Erica Samson Sanga1,2, Wondwossen Lerebo2,3, Adiel K Mushi4, Petra Clowes1,5, Willyhelmina Olomi1, Leonard Maboko1, Christina Zarowsky2,6
Linkage to care is the bridge between HIV testing and HIV treatment, care and support. In Tanzania, mobile testing aims to address historically low testing rates. Linkage to care was reported at 14% in 2009 and 28% in 2014. The study compares linkage to care of HIV-positive individuals tested at mobile/outreach versus public health facility-based services within the first 6 months of HIV diagnosis
Published at: 2017-04-12
Angela Cannas ,Glendah Kalunga ,Clare Green ,Ludovica Calvo,Patrick Katemangwe,Klaus Reither,Mark D. Perkins,Leonard Maboko,Michael Hoelscher,Elizabeth A. Talbot,Peter Mwaba,Alimuddin I. Zumla,Enrico Girardi,Jim F. Huggett,for the TB trDNA consortium
Molecular diagnosis using urine is established for many sexually transmitted diseases and is increasingly used to diagnose tumours and other infectious diseases. Storage of urine prior to analysis, whether due to home collection or bio-banking, is increasingly advocated yet no best practice has emerged. Here, we examined the stability of DNA in stored urine in two populations over 28 days.
Published at: 2009-09-10
Klaus Reither, Elmar Saathoff, Jutta Jung, Lilian T Minja, Inge Kroidl, Eiman Saad, Jim F Huggett, Elias N Ntinginya, Lucas Maganga, Leonard Maboko & Michael Hoelscher
The development and evaluation of rapid and accurate new diagnostic tools is essential to improve tuberculosis (TB) control in developing countries. In a previous study, the first release of a urine LAM-ELISA by Chemogen (Portland, USA) has been evaluated with a promising sensitivity and specificity for the diagnosis of pulmonary TB. In the present study, the now commercially available assay has been clinically assessed regarding its diagnostic value alone and in combination with clinical co-factors
Published at: 2009-08-28
Christof Geldmacher, Ian S. Metzler, Sodsai Tovanabutra, Tedi E. Asher, Emma Gostick, David R. Ambrozak, Constantinos Petrovas, Alexandra Schuetz, Njabulo Ngwenyama, Gustavo Kijak, Leonard Maboko, Michael Hoelscher, Francine McCutchan, David A. Price, Daniel C. Douek, Richard A. Koup
Human immunodeficiency virus-1 subtypes A and C differ in the highly conserved Gag-TL9 epitope at a single amino acid position. Similarly, the TL9 presenting human leukocyte antigen (HLA) class I molecules B42 and B81 differ only at 6 amino acid positions. Here, we addressed the influence of such minor viral and host genetic variation on the TL9-specific CD8 T-cell response. The clonotypic characteristics of CD8 T-cell populations elicited by subtype A or subtype C were distinct, and these responses differed substantially with respect to the recognition and selection of TL9 variants. Irrespective of the presenting.......
Published at: 2009-08-20
Christof Geldmacher, Ian S. Metzler, Sodsai Tovanabutra, Tedi E. Asher, Emma Gostick, David R. Ambrozak, Constantinos Petrovas, Alexandra Schuetz, Njabulo Ngwenyama, Gustavo Kijak, Leonard Maboko, Michael Hoelscher, Francine McCutchan, David A. Price, Daniel C. Douek, Richard A. Koup
Human immunodeficiency virus-1 subtypes A and C differ in the highly conserved Gag-TL9 epitope at a single amino acid position. Similarly, the TL9 presenting human leukocyte antigen (HLA) class I molecules B42 and B81 differ only at 6 amino acid positions. Here, we addressed the influence of such minor viral and host genetic variation on the TL9-specific CD8 T-cell response. The clonotypic characteristics of CD8 T-cell populations elicited by subtype A or subtype C were distinct, and these responses differed substantially with respect to the recognition and selection of TL9 variants. Irrespective of the presenting.......
Published at: 2009-08-20
Hannah Kibuuka ,David Guwatudde,Robert Kimutai,Lucas Maganga,Leonard Maboko,Cecilia Watyema,Fredrick Sawe,Douglas Shaffer,Dickson Matsiko,Monica Millard,Nelson Michael,Fred Wabwire-Mangen,Merlin Robb
HIV vaccine trials generally require that pregnant women are excluded from participation, and contraceptive methods must be used to prevent pregnancy during the trial. However, access to quality services and misconceptions associated with contraceptive methods may impact on their effective use in developing countries. We describe the pattern of contraceptive use in a multi-site phase I/IIa HIV Vaccine trial in East Africa (Uganda, Kenya and Tanzania) and factors that may have influenced their use during the trial.
Published at: 2009-04-10